Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression - PubMed (original) (raw)
Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression
Farhad Vesuna et al. Neoplasia. 2009 Dec.
Abstract
The cancer stem cell paradigm postulates that dysregulated tissue-specific stem cells or progenitor cells are precursors for cancer biogenesis. Consequently, identifying cancer stem cells is crucial to our understanding of cancer progression and for the development of novel therapeutic agents. In this study, we demonstrate that the overexpression of Twist in breast cells can promote the generation of a breast cancer stem cell phenotype characterized by the high expression of CD44, little or no expression of CD24, and increased aldehyde dehydrogenase 1 activity, independent of the epithelial-mesenchymal transition. In addition, Twist-overexpressing cells exhibit high efflux of Hoechst 33342 and Rhodamine 123 as a result of increased expression of ABCC1 (MRP1) transporters, a property of cancer stem cells. Moreover, we show that transient expression of Twist can induce the stem cell phenotype in multiple breast cell lines and that decreasing Twist expression by short hairpin RNA in Twist-overexpressing transgenic cell lines MCF-10A/Twist and MCF-7/Twist as well as in MDA-MB-231 partially reverses the stem cell molecular signature. Importantly, we show that inoculums of only 20 cells of the Twist-overexpressing CD44(+)/CD24(-/low) subpopulation are capable of forming tumors in the mammary fat pad of severe combined immunodeficient mice. Finally, with respect to mechanism, we provide data to indicate that Twist transcriptionally regulates CD24 expression in breast cancer cells. Taken together, our data demonstrate the direct involvement of Twist in generating a breast cancer stem cell phenotype through down-regulation of CD24 expression and independent of an epithelial-mesenchymal transition.
Figures
Figure 1
Cell surface expression of CD44 and CD24 in Twist-dysregulated breast cells. (A) Immunoblots showing the downregulation of Twist in MCF-10A/Twist, MCF-7/Twist, and MDA-MB-231 breast cancer cell lines by short hairpin RNA against Twist delivered using lentiviral vectors. Lower panels show Twist transient expression levels in MCF-10A and MCF-7 cell lines expressing Twist by retroviral delivery. The antibody against Twist was generated in-house and was validated. Actin was scored as loading control. (B) Flow cytometry analysis of various cell lines for CD44 and CD24 expression. Unstained and single-antibody stained cells were used as controls for setting the quadrants. The events in the lower right quadrant represent the CD44+/CD24-/low subpopulation. The analyzed data are represented as dot plots of (first row) immortalized normal mammary epithelial cell line MCF-10A and breast cancer cell lines MCF-7 and MDA-MB-231, (second row) stable Twistoverexpressing cell lines MCF-10A/Twist and MCF-7/Twist, (third row) transiently transduced Twist-expressing MCF-10A and MCF-7, and (fourth row) Twist knockdown in MCF-10A/Twist, MCF-7/Twist, and MDA-MB-231 breast cancer cells. Ten thousand viable cells were gated for each dot plot acquisition. Results are representative of five separate experiments.
Figure 2
Epithelial-mesenchymal marker expression in Twist cells. (A) Immunoblots showing epithelial marker E-cadherin and mesenchymal marker vimentin in transient knockdown of Twist in stable Twist-expressing cell lines MCF-10A/Twist and MCF-7/ Twist. (B) Immunoblots showing E-cadherin and vimentin in MCF-7 and MCF-7/Twist cells transiently expressing Twist. Transduced cells were lysed and immunoblotted with antibodies against E-cadherin, vimentin (Santa Cruz Biotechnology, Santa Cruz, CA), and Twist (in-house generated). Actin (Sigma-Aldrich) was used as loading control.
Figure 3
Efflux studies in MCF-7 and MCF-7/Twist cells. (A) Representative photomicrographs of Hoechst efflux staining in MCF-7/Twist cells compared with parental MCF-7 cells. The cells, after efflux, were photographed using a Nikon Eclipse 80i fluorescence microscope. (B) Histogram showing quantification of fluorescence intensity per cell. Cell fluorescence (n = 6) in the blue channel was analyzed using dedicated software developed in IDL programming environment that provides an operator-free segmentation of images and determines the average relative fluorescence per cell. Three images were analyzed per sample. (C) Histogram showing expression of drug transporters ABCG2, ABCC1, and ABCA1 in MCF-7/Twist and parental MCF-7 cells. (D) Histogram showing efflux of Rhodamine 123 stain in MCF-7/Twist and in MCF-7 cells. The amount of Rhodamine 123 dye in the cells was determined by flow cytometry. Results are representative of three separate experiments.
Figure 4
ALDH activity in Twist-dysregulated breast cells. Dot plots of various cell lines analyzed by flow cytometry for ALDH activity. Cells were treated with ALDEFLUOR in the presence or absence of ALDH inhibitor DEAB. After treatment, the samples were analyzed by flow cytometry for the presence of ALDH bright cells. The ALDH bright region was based on the control DEAB sample that was gated to have less than five events. The cell percentage numbers for ALDH positivity are indicated in the bottom right of each histogram. The values presented are the averages of three independent experiments. The analyzed data are represented as dot plots of (first row) parental MCF-10A and MCF-7 breast cancer cell lines, (second row) stable Twist-overexpressing MCF-10A/Twist and MCF-7/Twist breast cancer cell lines, (third row) breast cell lines MCF-10A and MCF-7 transiently transduced with Twist-expressing retroviral constructs, and (fourth row) Twist knockdown breast cancer cell lines MCF-10A/Twist and MCF-7/Twist. Results are representative of five separate experiments.
Figure 5
Self-renewal and mammosphere formation of Twist-expressing MCF-7 cells. MCF-7/Twist cells were stained with CD44 and CD24 antibodies and flow sorted to purify the CD44+/CD24-/low subpopulation. The purified MCF-7/Twist CD44+/CD24-/low subpopulation was propagated in culture, and the percentage of CD44 and CD24 cells was estimated by flow cytometry. (A) Histograms of chronological changes in the CD44+/CD24-/low subpopulation during a period of 13 generations. (B) qRT-PCR analysis of Twist, CD44, and CD24 transcript levels in the purified CD44+/CD24-/low versus CD44+/CD24+ subpopulations of cells. (C and D) Mammosphere formation by stable Twist-overexpressing cell lines, MCF-7/Twist, and MCF-10A/Twist. Top rows show phase-contrast photomicrographs of mammospheres at a magnification of x20. The lower rows show viability of the cells as indicated by the fluorescence of Calcein-AM stain. Data are represented as histograms on the right. Experiments were performed in quadruplicates and an average of five fields per well were counted.
Figure 6
Twist transcriptional regulation of CD24 expression. (A) Schematic representation of the CD24 promoter sequence showing the location of putative TWIST binding sites relative to the transcription start site (+1). Tick marks denote the canonical E-box sequences (CANNTG) to which Twist can potentially bind. The numbers above the tick marks indicate the relative position of E-box sequences within the promoter region. (B) Reporter assays were performed using CD24 promoter-reporter constructs in MCF-7 with exogenous Twist expression plasmid added and estimated for 2 days. The results of the promoter assays are represented as a histogram showing normalized luciferase readings in CD24 promoter activity. (C) Immunoblot analysis of cell extracts from MCF-7 and MCF-7/Twist cells scored for CD24 (Santa Cruz Biotechnology) and Twist protein expression. Actin was used as a loading control. (D and E) In vivo binding of Twist protein to the CD24 promoter sequence. ChIP was carried out using MCF-7/Twist cells and analyzed using CD24 promoter-specific primers by PCR. Identical volumes from the final precipitate were used for the PCRs except for the input, which was diluted 10-fold.
Figure 7
Growth of low inoculums of purified CD44+/CD24-/low and CD44+/CD24+ subpopulations in SCID mice. (A) Graphical representation of growth rates of orthotopic xenograft tumors using flow-sorted cells from the Twist+/CD44+/CD24-/low and CD44+/CD24+ subpopulations. We transplanted 100, 50, and 20 cells of the Twist+/CD44+/CD24-/low subpopulation, and 100 cells from the Twist+/CD44+/CD24+ subpopulation. Four mice per inoculum were used for this study. Significance was analyzed by a two-sided _t_-test (**P<.05, ***P <.005). (B) Twist immunohistochemical staining of representative tumors from the CD44+/CD24-/low and CD44+/CD24+ subpopulations. Photomicrographs were taken in bright field settings at a magnification of x40 using Nikon Eclipse 80i fluorescence microscope.
Similar articles
- Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.
Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, Korkaya H, Wicha MS, Lin J. Lin L, et al. PLoS One. 2013 Dec 23;8(12):e82821. doi: 10.1371/journal.pone.0082821. eCollection 2013. PLoS One. 2013. PMID: 24376586 Free PMC article. - Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Li W, et al. Sci Rep. 2017 Oct 23;7(1):13856. doi: 10.1038/s41598-017-14364-2. Sci Rep. 2017. PMID: 29062075 Free PMC article. - BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A, Paul BT, Sullivan LM, Sims H, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. Sinha A, et al. Oncotarget. 2017 Feb 7;8(6):10114-10135. doi: 10.18632/oncotarget.14357. Oncotarget. 2017. PMID: 28052035 Free PMC article. - Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H, Srour EF, Badve S. Nakshatri H, et al. Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60. doi: 10.2174/157488809787169110. Curr Stem Cell Res Ther. 2009. PMID: 19149630 Review. - Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer.
Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME, Thompson EW. Blick T, et al. J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):235-52. doi: 10.1007/s10911-010-9175-z. Epub 2010 Jun 4. J Mammary Gland Biol Neoplasia. 2010. PMID: 20521089 Review.
Cited by
- Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics.
BharathwajChetty B, Sajeev A, Vishwa R, Aswani BS, Alqahtani MS, Abbas M, Kunnumakkara AB. BharathwajChetty B, et al. Cancer Metastasis Rev. 2024 Mar;43(1):321-362. doi: 10.1007/s10555-024-10171-0. Epub 2024 Mar 22. Cancer Metastasis Rev. 2024. PMID: 38517618 Review. - Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X, Tian W, Jiang Z, Song Y, Leng X, Yu J. Li X, et al. Cancer Immunol Immunother. 2024 Jan 27;73(2):31. doi: 10.1007/s00262-023-03606-0. Cancer Immunol Immunother. 2024. PMID: 38279998 Free PMC article. Review. - Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma.
Todoroki K, Abe Y, Matsuo K, Nomura H, Kawahara A, Nakamura Y, Nakamura M, Seki N, Kusukawa J. Todoroki K, et al. Oncol Lett. 2024 Jan 4;27(2):79. doi: 10.3892/ol.2024.14213. eCollection 2024 Feb. Oncol Lett. 2024. PMID: 38249811 Free PMC article. - PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness.
Streitfeld WS, Dalton AC, Howley BV, Howe PH. Streitfeld WS, et al. Cancer Biol Ther. 2023 Dec 31;24(1):2271638. doi: 10.1080/15384047.2023.2271638. Epub 2023 Nov 6. Cancer Biol Ther. 2023. PMID: 37927213 Free PMC article. - Epigenetic regulation of breast cancer metastasis.
Thakur C, Qiu Y, Pawar A, Chen F. Thakur C, et al. Cancer Metastasis Rev. 2024 Jun;43(2):597-619. doi: 10.1007/s10555-023-10146-7. Epub 2023 Oct 19. Cancer Metastasis Rev. 2024. PMID: 37857941 Review.
References
- Knudson AG, Jr, Strong LC, Anderson DE. Heredity and cancer in man. Prog Med Genet. 1973;9:113–158. - PubMed
- Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer. 2003;3:832–844. - PubMed
- Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle. 2007;6:2332–2338. - PubMed
- Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous